期刊
ANTIVIRAL THERAPY
卷 16, 期 1, 页码 89-98出版社
INT MEDICAL PRESS LTD
DOI: 10.3851/IMP1699
关键词
-
资金
- Ministry of Education, Culture, Sports, Science and Technology in Japan
- Ministry of Health, Labour and Welfare in Japan
- Uehara Memorial Foundation
- Nagao Takeshi Nanbyo Foundation
- Kanagawa Nanbyo Foundation
- Mishima Kaiun Memorial Foundation
- Takeda Science Foundation
- ITSUU Laboratory Research Foundation
- Foundation of Total Health Promotion
Background: Human T-lymphotropic virus type-1 (HTLV-1) is a human retrovirus that causes HTLV-1-associated myelopathy/tropical spastic paraparcsis (HAM/TSP) and adult T-cell leukaemia (ATL). A higher viral load in individuals with HTLV-1 infection increases their risk of developing HAM/TSP and ATL. Moreover, the high proviral load is associated with the clinical progression of HAM/TSP. Reduction of the number of HTLV-1-infected cells is therefore crucial for preventing and treating HTLV-1-associated diseases. Recently, fucoidan, a complex sulphated polysaccharide derived from marine seaweed, has been demonstrated to exert inhibitory effects on HTLV-1 infection in vitro. In this study, we examined the in vivo effects of fucoidan on HTLV-1 infection. Methods: In this single-centre open-label trial, 13 patients with HAM/TSP were treated with 6 g fucoidan daily for 6-13 months. The HTLV-1 proviral DNA load and frequencies of HTLV-1-specific CD8(+)T-cells, natural killer cells, invariant natural killer T-cells and dendritic cells in the peripheral blood were analysed. Furthermore, the in vitro inhibitory effect of fucoidan on cell-tocell HTLV-1 infection was examined by using luciferase reporter cell assays. Results: Fucoidan inhibited the cell-to-cell transmission of HTLV-1 in vitro. Furthermore, fucoidan therapy resulted in a 42.4% decrease in the HTLV-1 proviral load without affecting the host immune cells. During the treatment, no exacerbation was observed. Four patients with HAM/TSP developed diarrhoea, which improved immediately after stopping fucoidan administration. Conclusions: Fucoidan is a new potential therapeutic agent for the prevention and treatment of HTLV-1-associated diseases.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据